Avalo Therapeutics (AVTX) Common Equity (2014 - 2026)
Avalo Therapeutics posted quarterly Common Equity of $68.3 million for Q1 2026, down 44.28% year-on-year from $122.6 million in Q1 2025, and down 17.74% on a QoQ basis from $83.0 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Common Equity data on file, last reported at $68.3 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity fell 44.28% year-over-year to $68.3 million; the trailing twelve-month figure through Mar 2026 stood at $68.3 million (down 44.28% YoY), and the FY2025 full-year result was $83.0 million, down 37.57% from the prior year.
- Common Equity for Q1 2026 stood at $68.3 million, down from $83.0 million in the prior quarter.
- Across five years, Common Equity topped out at $133.0 million in Q4 2024 and bottomed at -$112.5 million in Q1 2024.
- The 5-year median for Common Equity is $7.3 million (2023), against an average of $29.1 million.
- Peak annual rise in Common Equity reached 1721.36% in 2024, while the deepest fall reached 1695.79% in 2024.
- A 5-year view of Common Equity shows it stood at -$10.9 million in 2022, then soared by 166.92% to $7.3 million in 2023, then soared by 1721.36% to $133.0 million in 2024, then sank by 37.57% to $83.0 million in 2025, then dropped by 17.74% to $68.3 million in 2026.
- The last three Common Equity figures came in at $68.3 million (Q1 2026), $83.0 million (Q4 2025), and $91.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 68.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.32 Mn |
| Dec 31, 2025 | 83.05 Mn |
| Sep 30, 2025 | 91.55 Mn |
| Jun 30, 2025 | 104.57 Mn |
| Mar 31, 2025 | 122.62 Mn |
| Dec 31, 2024 | 133.03 Mn |
| Sep 30, 2024 | 21.08 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -112.54 Mn |
| Dec 31, 2023 | 7.30 Mn |
| Sep 30, 2023 | 14.70 Mn |
| Jun 30, 2023 | -6.97 Mn |
| Mar 31, 2023 | -6.27 Mn |
| Dec 31, 2022 | -10.92 Mn |
| Sep 30, 2022 | -2.03 Mn |
| Jun 30, 2022 | -5.95 Mn |
| Mar 31, 2022 | 6.34 Mn |
| Dec 31, 2021 | 23.08 Mn |
| Sep 30, 2021 | 40.31 Mn |
| Jun 30, 2021 | 21.59 Mn |
| Mar 31, 2021 | 33.16 Mn |
| Dec 31, 2020 | 24.56 Mn |
| Sep 30, 2020 | 38.57 Mn |
| Jun 30, 2020 | 50.58 Mn |
| Mar 31, 2020 | 25.59 Mn |
| Dec 31, 2019 | 21.00 Mn |
| Sep 30, 2019 | 18.22 Mn |
| Jun 30, 2019 | 17.70 Mn |
| Mar 31, 2019 | 23.12 Mn |
| Dec 31, 2018 | 20.91 Mn |
| Sep 30, 2018 | 19.51 Mn |
| Jun 30, 2018 | 19.22 Mn |
| Mar 31, 2018 | 24.58 Mn |
| Dec 31, 2017 | 27.86 Mn |
| Sep 30, 2017 | 22.12 Mn |
| Jun 30, 2017 | 3.14 Mn |
| Mar 31, 2017 | -425,758.00 |
| Dec 31, 2016 | 207,002.00 |
| Sep 30, 2016 | 586,827.00 |
| Jun 30, 2016 | 5.57 Mn |
| Mar 31, 2016 | 8.88 Mn |
| Dec 31, 2015 | 13.08 Mn |
| Sep 30, 2015 | -32.85 Mn |
| Dec 31, 2014 | -26.33 Mn |